KERX Financial Facts

Total general and administrative: 12.27M
Total research and development: 10.28M
See Full Income Statement

Total current liabilities: 18.51M
Total liabilities: 18.59M
See Full Balance Sheet

Keryx Biopharmaceuticals Inc. (KERX) Earnings

  |   Expand Research on KERX
Next EPS Date 11/4/14 *Est. EPS Growth Rate -71.4% *Last Qtr.
Average EPS % Beat Rate -46.9% Revenue Growth Rate N/A
Average % Move 1-Wk after EPS +3.3% Normal Earnings Time N/A
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
5/8/14 Q114 -$0.15-$0.08 -$0.07$10M$9.91M N/A Details
5/7/13 Q113 -$0.03-$0.01 -$0.02$7M$5.83M N/A Details
8/8/11 Q211 -$0.05-$0.03 -$0.02$5M$5M N/A Details
5/8/12 Q112 -$0.13-$0.12 -$0.01N/AN/A N/A Details
2/29/12 Q411 -$0.12-$0.14 +$0.02N/AN/A N/A Details
3/8/11 Q410 -$0.09-$0.06 -$0.03N/A$2.82M N/A Details
11/2/11 Q311 -$0.15-$0.12 -$0.03N/AN/A N/A Details
8/7/12 Q212 -$0.02-$0.09 +$0.07N/AN/A N/A Details